Innovative RBD Vaccine: Hope Against COVID-19
A new vaccine developed using RBD protein shows promise in fighting COVID-19.
Nur Amalia Limeilati, Reviany V. Nidom, Trilokita Tunjung Sari, Nurvita P. Kusumarahayu, Siti V. Fransiska, Setyarina Indrasari, Afrillia N. Garmana, Dhyan K. Ayuningtyas, Gembong S. Nugroho, Darsono, Maharani, Acep R. Wijayadikusumah, Elin Yulinah, I Ketut Adyana, Astria N. Nidom, Neni Nurainy, Chairul A. Nidom
― 6 min read
Table of Contents
In early 2020, a new virus called SARS-CoV-2 was identified, causing the COVID-19 pandemic. Governments around the world scrambled to find ways to protect their citizens, leading to the urgent need for effective Vaccines. Imagine a world where everyone is protected, and the virus is just a bad memory!
This led to a variety of vaccine candidates targeting different parts of the virus, especially the Spike (S) protein that allows the virus to enter human cells. A specific part of this protein, known as the receptor-binding domain (RBD), became an important target. Vaccines using RBD aim to create antibodies that block the virus from entering cells, reducing the chance of infection.
The Vaccine Journey
On the path to creating a solid vaccine, scientists developed several technologies. These include using nucleic acids (like mRNA), viral vectors, inactivated viruses, and even just bits of proteins. Many of these vaccines were approved under emergency use, but the process didn’t stop there.
By June 2021, over 2 billion doses were given, primarily in wealthier nations. Unfortunately, developing countries faced delays. To tackle this problem, efforts were made to boost local vaccine production. It was crucial to ensure that vaccines reached everyone, regardless of where they lived.
A promising vaccine was created using RBD protein from the virus, combined with ingredients that help boost the Immune Response. This vaccine was developed by collaborating teams from Indonesia and the U.S. The RBD protein was chosen because it could generate a strong immune response while minimizing possible side effects.
Clinical Trials and Studies
Preclinical Testing
Before a vaccine can be tested in humans, it undergoes rigorous testing in animals. This helps ensure Safety and effectiveness. For this RBD vaccine, several types of animals were used, including mice, rats, rabbits, and monkeys.
Ethical approval was secured for all procedures involving animals. The tests evaluated both safety and how well the vaccine could stimulate an immune response. In simple terms, scientists were checking if the vaccine made the animals' bodies fight back against the virus.
Study Groups
In these experiments, mice and other animals received different doses of the vaccine. The aim was to find out which doses worked best and whether the vaccine created enough antibodies to protect them from infection.
Researchers looked for signs of any harmful reactions, such as changes in weight or behavior. They also monitored blood samples to measure antibody levels. The animals were carefully observed for about two weeks after vaccination, ensuring everything was going smoothly.
Results
Mice Immunogenicity Studies
The experiments showed that the RBD vaccine created a strong immune response in mice. Those receiving the vaccine with special ingredients called adjuvants showed better results. They produced higher levels of antibodies after vaccination.
Interestingly, the mice that got the vaccine experienced a significant increase in antibodies after the second shot. This was good news, as it indicated the vaccine was doing its job and preparing the immune system to fight off the virus.
Safety Testing
Safety tests in rats and rabbits showed no concerning symptoms after vaccination. The animals gained weight and did not show signs of distress, suggesting the vaccine was safe. It was like a party without any wild surprises—you know, the kind where everyone leaves happy!
Non-Human Primates Testing
The final tests included monkeys, which are closer to humans in biology. They received the vaccine and were later exposed to the virus. Luckily, they showed no severe symptoms after being infected with SARS-CoV-2 variants.
This was a great sign, as it indicated that the vaccine could provide protection even in more complex living beings. It's like watching a superhero successfully save the day without breaking a sweat.
Conclusions and Future Steps
The development of this RBD vaccine is a step forward in the fight against COVID-19. It demonstrated that a safe and effective vaccine could be produced using a specific part of the virus, combined with the right helpers to make the immune response even stronger.
Next steps involve moving onto human trials to confirm the vaccine's effectiveness and safety in people. The goal is to create a widely available vaccine that can protect everyone—regardless of where they live—so they can return to normal life.
As the world continues to navigate through these challenging times, breakthroughs like this vaccine provide hope and a glimpse of a brighter future. Who wouldn't want a shot at a more carefree life, free from pandemic worries?
The Bigger Picture
The pandemic taught us many things, especially about the importance of global collaboration in science. Each vaccine developed adds another layer of protection against the virus—it's like building a strong wall brick by brick to defend against an invading army.
This RBD vaccine's potential opens doors to new research avenues and could lead to more vaccine innovations that tackle not just COVID-19 but other viruses too. Like a gardener planting new seeds for future blooms, researchers are constantly working to make our world safer.
Ultimately, while the scientific journey can be long and complex, the collective efforts of scientists, researchers, and healthcare professionals are paving the way for a healthier and happier world. So here's to the power of science and teamwork—may they continue to triumph and make the impossible possible!
Fun Facts About Vaccines
-
Not Just Needles! Vaccines have come a long way from simple injections. Some future vaccines might be delivered as nasal sprays or even edible forms.
-
Antibody Avengers! Antibodies are like superhero bodyguards for our cells, preventing intruders like viruses from causing trouble.
-
History of Vaccines: The first vaccine was developed over 200 years ago by Edward Jenner to protect against smallpox, and look how far we've come since then!
-
Global Collaboration: Scientists from different countries often work together, sharing research and findings to accelerate progress. It's like an international science club!
-
Inspiration for Comedies: The chaos of vaccine development, with its ups and downs, has inspired humorous content and sketches—it’s a serious job, but laughter can lighten the mood!
With such remarkable advancements in science, we can celebrate the achievements while hoping for even better outcomes. The world needs all the help it can get, and thanks to incredible minds and their relentless pursuit of knowledge, we are one step closer to beating COVID-19!
Original Source
Title: Study of the immunogenicity, efficacy and safety of recombinant RBD SARS-CoV-2 vaccine with CpG adjuvant in rodent, non-rodent and Maccaca fascicularis using Indonesian Strain Virus
Abstract: SARS-CoV-2 is the leading cause of the COVID-19 pandemic that causes acute respiratory syndrome, emerged in late 2019, and was declared a global pandemic on March 11th, 2020. A safe and effective vaccine that prevents SARS-CoV-2 infection or minimize SARS-CoV-2 disease burden is needed. However, in 2021, Low- and middle-income countries (LMICs) face challenges regarding supply of COVID-19 vaccines. Indonesia, as a public sector vaccine manufacturing in developing countries was developed COVID-19 vaccine using a platform based on recombinant subunit proteins, a Receptor Binding Domain (RBD) of SARS-CoV-2 formulated with combination of Alhydrogel and CpG Oligodeoxynucleotides 1018 (CpG). In this study, we report the preclinical study including immunogenicity, toxicity and efficacy of vaccine in animal models. The vaccine immunogenicity tested in mice and non-human primates, the toxicity was done in rodents and non-rodents and challenged study and efficacy was done in non-human primates (NHPs) model. The animal model was vaccinated intramuscularly (IM). The serology result in mice and non-human primates showed significant antibody titers and neutralizing antibody responses compared to the RBD formulations adjuvanted with Alhydrogel only. Safety study in Wistar rats and New Zealand rabbits for single-dose (acute toxicity) and repeated-dose (sub-chronic toxicity) showed no abnormalities in the animals organs and behaviors and no deaths were reported in tested animals. Two doses of vaccination have been shown to protect NHPs against SARS-CoV-2 infection, as detected by drastic viral reduction from sample swab in nasal, anal, trachea and nasal wash in 7 days after virus challenged, also viral load measurement from lung and BAL tissue showed negative result, which gave better result than negative control and control vaccine group. No evidence of disease enhancement was observed. These results support clinical development of SARS-CoV-2 vaccine, and in 2022 this vaccine has been approved for emergency use in Indonesia.
Authors: Nur Amalia Limeilati, Reviany V. Nidom, Trilokita Tunjung Sari, Nurvita P. Kusumarahayu, Siti V. Fransiska, Setyarina Indrasari, Afrillia N. Garmana, Dhyan K. Ayuningtyas, Gembong S. Nugroho, Darsono, Maharani, Acep R. Wijayadikusumah, Elin Yulinah, I Ketut Adyana, Astria N. Nidom, Neni Nurainy, Chairul A. Nidom
Last Update: 2024-12-20 00:00:00
Language: English
Source URL: https://www.biorxiv.org/content/10.1101/2024.12.18.629000
Source PDF: https://www.biorxiv.org/content/10.1101/2024.12.18.629000.full.pdf
Licence: https://creativecommons.org/licenses/by/4.0/
Changes: This summary was created with assistance from AI and may have inaccuracies. For accurate information, please refer to the original source documents linked here.
Thank you to biorxiv for use of its open access interoperability.